好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neutrophil–Lymphocyte Ratio Associated with Poor Clinical Outcome after Mechanical Thrombectomy Following Large Vessel Occlusion Stroke in Patients with COVID-19
Infectious Disease
S31 - Infectious Disease: Stroke and Infectious Diseases (4:40 PM-4:48 PM)
005

na

The neutrophil–lymphocyte ratio (NLR) is emerging as a biomarker in patients with a myriad of medical conditions. NLR has been confirmed as a potential short-term prognostic indicator for patients with COVID-19.
Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage and has been established as a predictor of disease progression and critical deterioration in COVID 19 [Jingyuan Liu]. We sought to describe the role of NLR in predicting poor outcome in patients COVID-19 patients undergoing mechanical thrombectomy  subset of consecutive COVID-19 patients with  acute ischemic stroke.

We evaluated COVID-19 patients with LVO Strokes enrolled into an international 12 center retrospective study of laboratory-confirmed COVID-19 consecutively admitted between March 1st and May 1st in 12. Admission WBC differentials (NLR) were analyzed using a cutoff of ≥ 7.2. Logistic regression models were generated. 

Out of a total of 6698 patients admitted with COVID-19 positive in 12 stroke centers during the study period, the incidence of large vessel occlusion stroke was 38/6698 (0.8%).   An elevated NLR and low TICI grade (TICI1 or TICI2a) are synergistically predictive of worse outcome (LR 11.65 p=0.0030). Patients with an NLR >7.2 were 6.8 times more likely to die (OR 6.8, CI95% 1.2-38.6, p=0.03) and almost 6 times more likely to have a poor outcome (OR 5.9, CI95% 1.3-27.3 , p=0.02). Patients with an NLR > 7.2 were almost 8 times more likely to require prolonged invasive mechanical ventilation (OR 7.8, CI95% 1.2-52.4, p=0.03).

An elevated NLR in the setting of COVID 19 patients with LVO strokes portends significantly worse outcomes and increased mortality regardless of TICI score indicating that the neuroinflammatory response in COVID-19 outweighs any potential benefit of a successful thrombectomy.

Authors/Disclosures
Fawaz Al-Mufti, MD (Westchester Medical Center at New York Medical College)
PRESENTER
Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Revalesio .
No disclosure on file
Hussein Alshammari, MD (Wmc) Dr. Alshammari has nothing to disclose.
Chirag Gandhi (Westchester Medical Center) Chirag Gandhi has nothing to disclose.
Stephan A. Mayer, MD (Henry Ford Hospital) Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phagenesis. Dr. Mayer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astra Zeneca. Dr. Mayer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. Dr. Mayer has stock in Neuroptics. Dr. Mayer has received publishing royalties from a publication relating to health care.